Simone Greven

USPTO Granted Patents = 20 (Patent Applications = 26)

CIPO Patents = 3 (Patent Applications = 19)

EPO Patents = 7 (Patent Applications = 38)

Average Co-Inventor Count = 10.1

ph-index = 5

Forward Citations = 93(Granted Patents)

Company Filing History:

14 out of 378

Bayer Pharma Aktiengesellschaft

patents

4 out of 12,157

Bayer Aktiengesellschaft

patents

4 out of 721

Bayer Intellectual Property Gmbh

patents

4. 1 out of 132

Seattle Genetics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

20 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12331094 - Atrial natriuretic peptide engrafted antibodies (2025-06-17),

2. 12144865 - Antibody drug conjugates with enzymatically cleavable groups (2024-11-19),

3. 12059472 - Prodrugs of cytotoxic active agents having enzymatically cleavable groups (2024-08-13),

4. 11806404 - Site specific homogeneous with KSP inhibitors (2023-11-07),

5. 11685714 - Prodrugs of cytotoxic active agents having enzymatically cleavable groups (2023-06-27),

6. 11660351 - Antibody drug conjugates (ADCs) having enzymatically cleavable groups (2023-05-30),

7. 11643469 - Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies (2023-05-09),

8. 11478554 - Antibody drug conjugates (ADCS) having enzymatically cleavable groups (2022-10-25),

9. 11123439 - Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups (2021-09-21),

10. 11071788 - Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies (2021-07-27),

11. 11001636 - Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies (2021-05-11),

12. 10973923 - Site specific homogeneous with KSP inhibitors (2021-04-13),

13. 10744205 - Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies (2020-08-18),

14. 10485880 - Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies (2019-11-26),

15. 10022453 - Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) (2018-07-17),

Title: Unveiling the Innovative Work of Simone Greven in Biomedical Therapeutics

Introduction:

Simone Greven, a distinguished inventor hailing from Dormagen, Germany, has established herself as a trailblazer in the field of biomedical therapeutics with a remarkable portfolio of 18 patents. Her innovative contributions in developing prodrugs and conjugates of cytotoxic agents have significantly advanced the treatment and prevention of hyperproliferative disorders, including various types of cancers.

Latest Patents:

Simone's recent patents showcase her groundbreaking work in enhancing the efficacy of cytotoxic drugs through novel prodrugs and conjugates. One such invention involves structurally modified prodrugs with asparagine derivatives as cleavage sites for tumor-associated proteases like legumain. These prodrugs release cytotoxic agents, such as kinesin spindle protein inhibitors, upon cleavage, offering targeted treatment for hyperproliferative and angiogenic disorders, notably cancers. Another patent focuses on site-specific binder drug conjugates of kinesin spindle protein inhibitors, underscoring their potential in monotherapy or combination treatments for various diseases.

Career Highlights:

Simone Greven has left an indelible mark on the industry through her tenure at Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. Her expertise and leadership have propelled the development of innovative therapeutic solutions, positioning her as a key figure in advancing biomedical research and drug development.

Collaborations:

Throughout her career, Simone has collaborated with esteemed colleagues such as Hans-Georg Lerchen and Christoph Mahlert. Together, they have synergized their knowledge and skills to drive forward cutting-edge projects, fostering a culture of innovation and excellence in their endeavors.

Conclusion:

In conclusion, Simone Greven's visionary contributions to the field of biomedical therapeutics stand as a testament to her ingenuity and dedication to improving patient outcomes. Her prolific patent portfolio and collaborative spirit underscore her significant impact on the industry, paving the way for transformative advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.